Y90 Radioembolization - Use in Early Stage HCC and as Bridge to Transplant
|Activity Title||Y90 Radioembolization - Use in Early Stage HCC and as Bridge to Transplant|
|Accreditation Type||AMA PRA Category1 Credit(s)|
|Release Date||November 1, 2020|
|Expiration Date||November 31, 2021|
|Estimated Time to Complete Activity||60 minutes|
- Understand current practice patterns and applications of Y90 in the setting of early-stage HCC
- Participate in conversations about recently published data on use of Y90 in UNOS T1/T2 stages
- Identify potential limitations of the currently available scientific data and discuss strategies to address this in tumor-board-like conversations in their institutions.
STATEMENT OF NEED
Hepatocellular carcinoma (HCC) is one of the fastest growing cancers worldwide. While early stage disease might be amenable to curative treatments, loco-regional and systemic therapy is used for the majority of cases with intermediate to advanced stage disease. Due to the lack of effective systemic therapies for HCC, researchers have been investigating the use of locoregional tumor control with Yttrium-90 (Y90) radioembolization. Currently, there are two approved available Y90 devices for administration and numerous ongoing trials aimed at exploring the current and future utility of radioembolization in hepatic malignancies. A new and special role for Y90 has been recently investigated in patients with early stage disease, specifically with UNOS Stage 1/2 as well as its use as a bridge to transplant. This activity will discuss the recently published data (Gabr A, Hepatology & Journal of Hepatology, 2020) and consider Y90 as a possible regional option for those conditions. This activity is developed to educate clinicians on newer evidence and how to apply the information to their current practice of treating patients with HCC.
Riad Salem, MD, MBA
Professor of Radiology, Medicine, and Surgery Chief, Section of Vascular and Interventional Radiology
Vice-Chair, Image-Guided Therapy
Department of Radiology
William Rilling, MD, FSIR
Medical College of Wisconsin
Nishita Kothary, MD
Greg Nadolski, MD
University of Pennsylvania
Nicholas Fidelman, MD
University of California San Francisco
Jointly provided by The France Foundation and The Society of Interventional Oncology:
This activity is intended for interventional radiologists, hepatologists, radiation, medical and surgical oncologists, transplant surgeons, and physicists who treat patients with hepatic malignances.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and The Society of Interventional Oncology. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.
The France Foundation designates this internet live course for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This credit will be free to SIO members.
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and The Society of Interventional Oncology (SIO) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and SIO resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and SIO seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and SIO are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
ACTIVITY STAFF DISCLOSURES:
The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.
The planners, reviewers, editors, staff, CME committee, or other members at The Society of Interventional Oncology who control content have no relevant financial relationships to disclose.
FACULTY DISCLOSURES-ACTIVITY FACULTY:
The following faculty report that they have relevant financial relationships to disclose:
- Riad Salem has consulted (non-CE) for Boston Scientific, Cook, Eisai, AstraZeneca, Sirtex, and Genentech. He has contracted research for Boston Scientific.
- Dr. David Madoff has consulted (non-CE) for Boston Scientific, Sirtex, GE Healthcare, Merck, and Guerbet.
- Dr. William Rilling has consulted (non-CE) for B Braun, Boston Scientific, Terumo, BD/Bard, Sirtex, and Varian. He serves a contract researcher for Sirtex and Instylla.
- Dr. Nicholas Fidelman has received research grants from Merck, Boston Scientific, and Sirtex.
- Dr. Nishita Kothary has consulted for Quantum Surgical and serves as a contract researcher for EchoPixel. She is a stockholder of Neptune Medical.
The faculty listed below report that they have no relevant financial relationships to disclose:
- Dr. Gregory Nadolski
COMMERCIAL SUPPORT ACKNOWLEDGMENT
This activity is supported by an educational grant from Boston Scientific Corporation.
DISCLOSURE OF UNLABELED USE
TFF and SIO require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and SIO do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
The France Foundation and The Society of Interventional Oncology present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, The Society of Interventional Oncology, and the commercial supporter assume no liability for the information herein.
Copyright © 2020 by The Society of Interventional Oncology. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:
- The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
- Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.
The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.
The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.
METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT
Technical Requirements: http://www.francefoundation.com/general-requirements.html
- There are no fees for participating in and receiving credit for this activity as an SIO member.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
- To request credit, you must complete the webinar in its entirety
This site and its activities are best viewed using the latest versions of the Chrome, Edge, Firefox and Safari browsers. For interactive content a broadband connection is required. For CME/CE activities featuring audio you must have a sound card and speakers.
HOW TO CLAIM YOUR CME CREDITS
SIO Member Instructions
Please email education@sio-central for instructions on how to receive your CME Credits.
SIO Non-Member Instructions
Please follow the instructions below:
- Click here to log into your SIO online account *
- Click here and add your Y90 Webinar CME credits to your shopping cart
- In the lower right corner of the webpage, click "add to cart"
- In the upper left corner of the webpage, click "view cart"
- Click "checkout"
- Review your billing information and click "OK"
- Complete your payment using your preferred payment method
- You will receive a confirmation email containing final instructions for obtaining your CME credits
* If you do not already have an SIO online account, you can create your free guest account by clicking here.
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or email@example.com.